Sep 07, 2021
|
MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Metastatic Breast Cancer
|
|
Sep 02, 2021
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Aug 05, 2021
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Jul 29, 2021
|
MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results
|
|
Jul 22, 2021
|
MacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call
|
|
Jun 16, 2021
|
MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
|
|
May 19, 2021
|
MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting
|
|
May 19, 2021
|
MacroGenics to Participate in Upcoming Investor Conference
|
|
Apr 29, 2021
|
MacroGenics Provides Update on Corporate Progress and First Quarter 2021 Financial Results
|
|
Apr 19, 2021
|
MacroGenics Announces Date of First Quarter 2021 Financial Results Conference Call
|
|
Apr 10, 2021
|
MacroGenics Announces Presentations at the 2021 AACR Annual Meeting
|
|
Feb 26, 2021
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Feb 25, 2021
|
MacroGenics Provides Update on Corporate Progress and 2020 Financial Results
|
|
Feb 18, 2021
|
MacroGenics Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call
|
|
Feb 11, 2021
|
MacroGenics Names Federica O’Brien to its Board of Directors
|
|
Feb 11, 2021
|
MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte
|
|
Feb 08, 2021
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Jan 25, 2021
|
MacroGenics Announces Publication of SOPHIA Trial Results for MARGENZA™ in JAMA Oncology
|
|
Jan 11, 2021
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Dec 22, 2020
|
MacroGenics Announces MGD019 Publication in Cell Reports Medicine
|
|
Dec 18, 2020
|
MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule
|
|
Dec 16, 2020
|
MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
|
|
Dec 07, 2020
|
MacroGenics Presents Tebotelimab Data in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma at the 2020 ASH Annual Meeting
|
|
Dec 06, 2020
|
MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
|
|
Nov 30, 2020
|
MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab
|
|